Urinary Incontinence Clinical Trials 2024

Urinary Incontinence Clinical Trials 2024

Urinary Incontinence research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in urinary incontinence clinical trials today.

Urinary Incontinence Clinical Trials

Here are the 6 most popular medical studies for urinary incontinence

Popular filter options for urinary incontinence trials

Urge Incontinence Clinical Trials

View 53 Urge Incontinence medical studies.

Urge Urinary Incontinence Clinical Trials

View 47 Urge Urinary Incontinence medical studies.

Urinary Incontinence Clinical Trials With No Placebo

View 87 urinary incontinence medical studies that do not have a placebo group.

View More Urinary Incontinence Trials

See another 69 medical studies focused on urinary incontinence.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to urinary incontinence

What are the top hospitals conducting urinary incontinence research?

When it comes to addressing the challenges of urinary incontinence, several top hospitals are leading the way with their innovative clinical trials. In Albuquerque, New mexico, the University of New Mexico is making significant strides by currently conducting four active trials focused on urinary incontinence. Their commitment to finding solutions for this condition can be traced back to 2017 when they recorded their first trial. Meanwhile, in Pittsburgh at the University of Pittsburgh, researchers are working diligently on three ongoing urinary incontinence trials and have an impressive history of 13 conducted studies since initiating their first trial back in 2002.

The University of Colorado in Denver has also prioritized research on urinary incontinence with two active clinical trials aimed at advancing treatment options. While still relatively new to exploring this condition, having commenced their first trial as recently as 2019, they demonstrate a dedicated approach towards improving quality of life for those affected by urinary incontinence. Similarly, at the University of Texas Medical Branch located in Galveston, researchers are conducting two current clinical trials focusing on this condition. Despite sharing a comparable number of ongoing and historical trials with the University of Colorado (2 all-time), their efforts only began more recently alongside the University of New Mexico's pioneering investigations starting from 2017.

Joining these esteemed institutions is Northwestern Medicine based out Chicago where scientists have launched two active urinary incontinence trials contributing vital data toward future advancements. Having started just last year recording its inaugural trial during2020;Northwestern Medicine emphasizes that even recent findings hold immense value within medical research

These hospitals represent beacons for individuals who struggle with urinary incontinence—a common yet often stigmatized condition—offering hope through cutting-edge research and potential breakthroughs that may revolutionize treatment options soon enough

Which are the best cities for urinary incontinence clinical trials?

Pittsburgh, Pennsylvania, stands out as the leading city for urinary incontinence clinical trials with 9 active studies focused on treatments such as Comparator, Trospium, and Botox A® injection. Birmingham, Alabama follows closely behind with 6 ongoing trials exploring interventions like Hip Muscle Exercises and Topical vaginal estrogen group. San Diego, California also offers promising research opportunities with 6 active trials investigating options such as Beta-3 receptor agonist oral medication and transcutaneous tibial nerve stimulation (TTNS). Cleveland, Ohio contributes to the field with 5 ongoing studies examining technologies like Testing closed-loop system in an ambulatory setting and AMDC-USR (iltamiocel). Finally, Royal Oak, Michigan provides further insights through its 4 active trials studying therapies like Emsella Chair Active Treatment and Urodynamic testing and LLP with and without pudendal nerve stimulation. These cities offer individuals suffering from urinary incontinence access to cutting-edge clinical trials that may lead to improved management strategies for this condition.

Which are the top treatments for urinary incontinence being explored in clinical trials?

Clinical trials exploring treatments for urinary incontinence have identified several promising options. Leading the pack is eCoin Tibial Nerve Stimulation, currently being tested in two active trials dedicated to urinary incontinence. Since its introduction in 2018, it has been involved in a total of three clinical trials focused on this condition. Another contender is Pessary Intervention, with one ongoing trial and one all-time trial specifically targeting urinary incontinence since its listing in 2023. Additionally, the Adjustable Transobturator Male System shows promise as a potential treatment option, with one ongoing trial and one all-time trial dedicated to addressing urinary incontinence since its first appearance on the scene back in 2022. These innovative approaches offer hope for individuals seeking effective solutions to manage their symptoms of urinary incontinence.

What are the most recent clinical trials for urinary incontinence?

Exciting advancements are being made in clinical trials for urinary incontinence, offering hope to those who struggle with this condition. One notable trial focuses on the effectiveness of intra-detrusor OnabotulinumtoxinA injection as a treatment option. This study is currently in Phase 2 and Phase 3, with results expected to be available since July 13th, 2023. Another promising trial explores the use of a beta-3 receptor agonist oral medication for managing urinary incontinence. This Phase 4 trial has become available since June 6th, 2023. Furthermore, Botox at low doses is also being investigated as a potential solution through a combined Phase 1 and Phase (2) study that became accessible starting from May12th,2023 . With these groundbreaking studies underway and more research taking place involving medications like mirabegron and bupivacaine-meloxicam , we can anticipate progress towards improved treatments for urinary incontinence.

What urinary incontinence clinical trials were recently completed?

A recent completion in the field of urinary incontinence clinical trials is the investigation of Gefapixant, sponsored by Merck Sharp & Dohme Corp. This trial concluded in May 2020 and aimed to explore the potential effectiveness of Gefapixant as a treatment for urinary incontinence. The results from such studies contribute to advancing our understanding and developing novel approaches to managing this common condition that affects many individuals worldwide.